Innoviva, Inc.

NASDAQ:INVA

19.54 (USD) • At close September 18, 2024
Bedrijfsnaam Innoviva, Inc.
Symbool INVA
Munteenheid USD
Prijs 19.54
Beurswaarde 1,222,471,250
Dividendpercentage 0%
52-weken bereik 12.22 - 20.19
Industrie Biotechnology
Sector Healthcare
CEO Mr. Pavel Raifeld C.F.A.
Website https://www.inva.com

An error occurred while fetching data.

Over Innoviva, Inc.

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium

Vergelijkbare Aandelen

Adaptive Biotechnologies Corporation logo

Adaptive Biotechnologies Corporation

ADPT

4.61 USD

SomaLogic, Inc. logo

SomaLogic, Inc.

SLGC

2.1 USD

Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc.

ALLO

2.88 USD

Instil Bio, Inc. logo

Instil Bio, Inc.

TIL

66.1 USD

NGM Biopharmaceuticals, Inc. logo

NGM Biopharmaceuticals, Inc.

NGM

1.54 USD

Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc.

AGIO

45.54 USD

RadNet, Inc. logo

RadNet, Inc.

RDNT

67.11 USD

Outset Medical, Inc. logo

Outset Medical, Inc.

OM

0.65 USD

Celularity Inc. logo

Celularity Inc.

CELU

2.56 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)